Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bill Williams says HLA matching was not as critical for Bria-IMT when combined with an immune checkpoint inhibitor, so BriaCell is not matching patients for that product. The company is instead building HLA matching into its next-generation Bria-OTS and OTS Plus pipelines as those programs advance.

Related Insights

In a UK-wide immuno-oncology program, John Baker says IMU's pre-treatment immune profile separates patients likely to respond to anti-PD-L1 or checkpoint inhibitor combinations. It also flags before the first dose who may suffer severe immune-mediated adverse events, so clinicians can monitor and manage those patients more actively. Response rates are only 30-40%.

Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.

Clinicians are far more cautious using immunotherapy in organ transplant recipients than in patients with autoimmune disease. The risk of irreversible graft rejection is a major deterrent, reserving checkpoint inhibitors only for when no other treatment options exist.

Expanding T-cell engagers into large autoimmune indications is strategically attractive, but HLA-restricted modalities introduce logistical hurdles around patient screening. Routine oncology care already accommodates HLA typing into clinical workflows, whereas massive autoimmune populations cannot easily support routine typing. Focusing initial clinical development on oncology validates the platform where patient stratification is already feasible.

The initial hope for a revolution across many immune checkpoints has faded. With most targets outside of PD-1 failing to deliver, investors and pharma have grown fatigued. This disappointment has accelerated the industry's pivot towards other modalities like ADCs and cell therapies.

Bill Williams says BriaCell's engineered OTS cell lines express 15 HLA molecules across four lines. That lets them single-match over 99% of the population and double-match over 90%, making a personalized off-the-shelf therapy practical after only a one-week saliva test rather than complex tumor sequencing.

While targeting intracellular peptide-MHC complexes opens the entire proteome as potential cancer targets, the approach is limited by HLA restriction. This means a drug might only be applicable to 30-40% of patients, a major commercial and clinical drawback that complicates development despite the potential for exquisite specificity.

Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.

Bill Williams says BriaCell's phase 3 seeks a 40% reduction in mortality. If it misses that, the company can continue and aim for a 30% reduction; FDA agreed either result would support full approval for the therapy, so no separate confirmatory study would be needed.

Unlike many cell therapies, Rion's platelet-derived exosomes are devoid of the self/non-self surface markers that trigger immune rejection. This "immune privilege" is a critical biological advantage, allowing the product to be used as a universal, off-the-shelf therapy for any patient without needing donor matching.